Human hepatocytes are the model of choice for pharmacotoxicological studies, but their acquisition is often problematic due to ethical and logistical difficulties. The UK Human Tissue Bank is a not-for-profit organisation that acquires and processes human tissue, with a specialist interest in the isolation of human hepatocytes. A recent in-house survey of the processing of liver tissue over 1 year revealed that freshly isolated hepatocytes were underutilised due to mismatched consumer demand, despite the published need for them. We present the results of a telephone survey to investigate the reasons behind this paradox. This survey highlighted some problem areas, including “out of hours” availability of cells and personnel difficulties, but overall, demonstrated the value of such a service, with numerous researchers taking advantage of available good quality human hepatocytes. Although further work is required in optimising long-term storage protocols through cryopreservation, we have demonstrated that tissue handling of this type can be successful and beneficial to the pharmaceutical and biotechnology industries.
De SousaG., DouM., BarbeD., LacarelleB., PlacidiM., & RahmaniR. (1991). Freshly isolated or cryopreserved human hepatocytes in primary culture: influence of drug metabolism on hepatotoxicity. Toxicology in Vitro5, 483–486.
2.
DouM., De SousaG., LacarelleB., PlacidiM., Lechene de la PorteP., DomingoM., LafontH., & RahmaniR. (1992). Thawed human hepatocytes in primary culture. Cryobiology29, 454–469.
3.
HengstlerJ.G., RingelM., BiefangK., HammelS., MilbertU., GerlM., KlebachM., DienerB., PlattK.L., BottgerT., SteinbergP., & OeschF. (2000). Cultures with cryopreserved hepatocytes: applicability for studies of enzyme induction. Chemico-Biological Interactions125, 51–73.
4.
LiA.P., LuC., BrentJ.A., PhamC., FackettA., RueggC.E., & SilberP.M. (1999). Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug–drug interaction potential. ChemicoBiological Interactions121, 17–35.
5.
MagantoP., CienfuegosJ.A., SantamariaL., ErolesG., AndresS., Castillo-OlivaresJ.L., & MunicioA.M. (1988). Cryopreservation and transplantation of hepatocytes: an approach for culture and clinical application. Cryobiology25, 311–322.
6.
PapaloisA., ArkadopoulosN., KostopanagiotouG., TheodorakisK., PeveretosP., GolematisB., & PapadimitriouJ. (2001). Experimental xenotransplantation of fresh isolated and cryopreserved pig hepatocytes: a biochemical and morphological study. Transplanation Proceedings29, 2096–2098.
7.
SarkisR., BenoisthS., HonigerJ., BaudrimontM., DeleloR., BalladurP., CapeauJ., & NordlingerB. (2000). Transplanted cryopreserved encapsulated porcine hepatocytes are as effective as fresh hepatocytes in preventing death from acute liver failure in rats. Transplantation70, 58–64.
8.
SechserA., OsorioJ., FreiseC., & OsorioR.W. (2001). Artificial liver support devices for fulminant liver failure. Clinics in Liver Disease5, 415–430.
9.
StromS.C., ChowdhuryJ.R., & FoxI.J. (1999). Hepatocyte transplantation for the treatment of human disease. Seminars in Liver Disease19, 39–48.
10.
DemetriouA.A., WatanabeF., & RozgaJ. (1995). Artificial hepatic support systems. Progress in Liver Disease12, 331–348.
11.
DowlingD.J., & MutimerD.J. (1999). Artificial liver support in acute liver failure. European Journal of Gastroenterology and Hepatology11, 991–996.
TingP.P., & DemetriouA.A. (2000). Clinical experience with artificial liver support systems. Canadian Journal of Gastroenterology14, 79–84.
14.
TsiaoussisJ., NesomeP.N., NelsonL.J., HayesP.C., & PlevrisJ.N. (2001). Which hepatocyte will it be? Hepatocyte choice for bioartificial liver support systems. Liver Transplantation7, 2–10.
15.
RozgaJ., WilliamsF., RoM-S., NeuzilD.F., GiorgioT.D., BackfishG., MoscioniA.D., HakimR., & DemetriouA.A. (1993). Development of a bioartificial liver: properties and function of a hollow-fibre module inoculated with liver cells. Hepatology17, 258–265.
16.
WatanabeF.D., MullonC.J-P., HewittW.R., ArkadopoulosN., KahakuE., EguchiS., KhaliliT., AmaoutW., ShackletonC.R., RozgaJ., SolomonB., & DemetriouA.A. (1997). Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase 1 clinical trial. Annals of Surgery225, 484–494.
17.
RozgaJ., PodestaL., LePageE.B., MorsianiE., MoscioniA.D., HoffmanA., SherL., VillamilF., WoolfG., McGrathM., KongL., RosenH., LanmanT., VierlingJ., MakowkaL., & DemetriouA.A. (1994). A bioartificial liver to treat severe acute liver failure. Annals of Surgery219, 538–546.
18.
SheilA.G.R., SunJ., MearsD.C., WaringM., WoodmanK., JohnstonB., HorvatM., WatsonK.J., KoutalistrasN., & WangL-S. (1996). Preclinical trial of a bioartificial liver support system in a porcine fulminant hepatic failure model. The Australian and New Zealand Journal of Surgery66, 547–552.
19.
CoundourisJ.A., GrantM.H., EngesetJ., PetrieJ.C., & HawksworthG.M. (1993). Cryopreservation of human adult hepatocytes for use in drug metabolism and toxicity studies. Xenobiotica23, 1399–1409.
20.
SeglenP.O. (1976). Preparation of isolated rat liver cells. Methods in Cell Biology13, 29–83.
UK Department of Health (2001). The Royal Liverpool Children's Inquiry: Summary and Recommendations, 32 pp. London, UK: Department of Health.
23.
UK Department of Health (2000). Organ Retention — Interim Guidance on Post-mortem Examination to the NHS, 1 p. London, UK: Department of Health.
24.
UK Department of Health (2001). Organ Retention — Amended Guidance, 2 pp. London, UK: Department of Health.
25.
UK Department of Health (2002). Department of Health Response to Recommendations Investigation into Organ Retention at Central Manchester and Manchester Children's University Hospitals, 20 pp. London, UK: Department of Health.
26.
UK Department of Health (2001). Research Governance Framework for Health and Social Care, 50 pp. London, UK: Department of Health.
27.
SerrarH., El-KadiA., Du SouichP., & HaddadP. (1999). Cytochrome P-450 content and activity after cold storage of rat hepatocytes in University of Wisconsin and sodium-lactobionate-sucrose solutions. Liver Transplantation Surgery5, 119–125.
28.
KasaiS., & MitoM. (1993). Large-scale cryopreservation of isolated dog hepatocytes. Cryobiology30, 1–11.
29.
KoebeH.G., DunnJ.C.Y., TonerM., SterlingL.M., HubelA., CravalhoE.G., YarmushM.L., & TompkinsR.G. (1990). A new approach to the cryopreservation of hepatocytes in a sandwich culture configuration. Cryobiology27, 576–584.
LawrenceJ.N., & BenfordD.J. (1991). Development of an optimal method for the cryopreservation of hepatocytes and their subsequent monolayer culture. Toxicology in Vitro5, 39–51.
32.
LiA.P., GoryckiP.D., HengstlerJ.G., KedderisG.L., KoebeH.G., RahmaniR., de SousasG., SilvaJ.M., & SkettP. (1999). Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics: consensus of an international expert panel. ChemicoBiological Interactions121, 117–123.
33.
LoretzL.J., LiA.P., & FlyeM.W. (1989). Optimisation of cryopreservation procedures for rat and human hepatocytes. Xenobiotica19, 489–498.
34.
RueggC.E., SilberP.M., MughalR.A., IsmailJ., LuC., BodeD.C., & LiA.P. (1997). Cytochrome-P450 induction and conjugation metabolism in primary human hepatocytes after cryopreservation. In Vitro Toxicology10, 217–222.
OrrS., AlexandreE., ClarkB., CombesR., FelsL.M., GrayN., Jonsson-RylanderA-C., HelinH., KoistinenJ., OinonenT., RichertL., RavidR., SalonenJ., TeesaluT., ThaslerW., TraffordJ., van der ValkJ., von VersenR., WeissT., WomackC., & YlikomiT. (2002). The establishment of a network of European research tissue banks. Cell and Tissue Banking3, 133–137.
